Sanofi

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.

The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.

The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.

The pharma firm joins Pfizer Canada and AstraZeneca in the National Access Project, which tests tumors for mutations to match patients with potential therapies.

The two methods could shorten the detection time by eliminating the need to amplify the virus with in vitro cell culture.

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013

Pages

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.